home All News open_in_new Full Article

Entos Pharmaceuticals Announces $198.5 Million Partnership with the Governments of Canada and Alberta to Accelerate Biomanufacturing of Fusogenix PLV Next Generation Therapeutics

This investment will help build a 103,000-square-foot R&D center and a GMP manufacturing facility in Edmonton, Alberta. The biomanufacturing facility will develop and produce the Entos Fusogenix PLV drug delivery platform and the next generation of medicines. EDMONTON, Alberta — Entos® Pharmaceuticals (Entos), a clinical-stage genetic medicines company committed to using its Fusogenix™ PLV™ technology […]



Entos Pharmaceuticals is partnering with the Canadian and Alberta governments for a $198.5 million project, including $77.5 million in government funding, to build an R&D center and GMP biomanufacturing facility in Edmonton, Alberta. This facility will develop Entos' Fusogenix PLV drug delivery platform and next-generation therapeutics, fostering collaborations and strengthening Canada's biopharmaceutical sector.

today 65 h. ago attach_file Economics

attach_file Society
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Culture
attach_file Events
attach_file Events
attach_file Sport
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Other
attach_file Other
attach_file Economics
attach_file Events
attach_file Sport
attach_file Other
attach_file Economics


ID: 3649265609
Add Watch Country

arrow_drop_down